The gut microbiota plays an important role in controlling atherosclerosis progression to support the link between the gut and coronary heart disease. Recent studies have shown that an imbalance in the gut-heart axis due to the gut microbiota plays an important role in atherosclerosis progression. The gut microbiota promotes the development of atherosclerosis by producing intermediate metabolites, including TMAO, LPS, PAGln and reducing butyrate. TMAO and PAGln might be potential biomarkers of coronary heart disease. Many studies have shown that butyrate-producing bacteria prevent atherosclerosis progression by producing butyrate and maintaining the bacterial balance, the intestinal barrier function and the expression of various genes, including those encoding lipids and those related to immunity, inflammation, differentiation, apoptosis, phagocytosis and efferocytosis. This review focuses on recent advances in our understanding of the interplay between butyrate-producing bacteria and the gut-heart axis in atherosclerosis.
Keywords: Atherosclerosis; Butyrate; Gut-heart axis; LPS; PAGln; TMAO.
Copyright © 2020 Elsevier B.V. All rights reserved.